GTC
ADAP

Ghost Tree Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

Ghost Tree Capital’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$407K – 67
2016
Q1 		$407K Sell
50,000
-160,000
-76% -$1.31M 0.23% 48
2015
Q4 		$2.53M Buy
+210,000
New +$2.06M 1.04% 33
2015
Q3 		– Sell
-76,850
Closed -$1.41M – 75
2015
Q2 		$1.41M Buy
+76,850
New +$1.32M 0.46% 55

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ghost Tree Capital's ADAP Position: Q2 2016 in Review

Ghost Tree Capital sold out of Adaptimmune Therapeutics (ADAP) in Q2 2016, closing a stake of 50,000 shares — an estimated $407K sold.

Ghost Tree Capital first reported a position in ADAP in Q2 2015 and held it in 3 quarters. The position peaked at $2.53M in Q4 2015. 47 funds tracked by Wall St. Rank hold ADAP as of Q2 2016.

  • Ghost Tree Capital reported no remaining Adaptimmune Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Ghost Tree Capital sold 50,000 Adaptimmune Therapeutics shares in Q2 2016, an estimated $407K.
  • Ghost Tree Capital first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 3 quarters.
  • Ghost Tree Capital's Adaptimmune Therapeutics position peaked at $2.53M in Q4 2015.
  • 47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2016.

Based on Ghost Tree Capital's 13F filing for Q2 2016, filed 12 Aug 2016.